SYRE
Spyre Therapeutics Inc.
87.10$
-1.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -36.3% | +1,219.2% | +73.5% | -16.4% | +38.6% | +7.0% | +94.3% | -32.0% | -35.3% | +380.5% | +78.0% | +27.8% | |
| – | -40.6% | +1,302.4% | +73.5% | -17.2% | +39.4% | -2.8% | +101.0% | -34.0% | -37.0% | +448.6% | +78.2% | +27.8% | |
| – | -43.1% | +1,019.8% | +63.0% | -73.2% | +75.2% | -14.3% | +368.0% | -83.2% | +130.2% | +441.8% | -52.7% | -4.1% | |
| – | -43.1% | +1,163.8% | +92.1% | -20.8% | +48.1% | -3.4% | +103.3% | -36.3% | -40.2% | +509.0% | +77.8% | +25.4% | |
| – | – | – | -28.4% | +153.3% | -90.3% | – | – | – | -54.0% | – | – | – | |
| – | -25.1% | +141.0% | +60.7% | +40.1% | +79.6% | +124.1% | -5.7% | +19.3% | -19.8% | +657.4% | -42.6% | -31.0% | |
| – | -25.1% | +138.5% | +57.2% | +42.0% | +81.9% | +79.3% | -10.4% | +22.5% | -27.2% | +118.2% | +69.1% | +8.6% | |
| – | – | – | – | – | – | – | -15.8% | +36.7% | +43.3% | – | – | – | |
| – | +59.0% | -49.0% | -4.5% | +131.5% | +70.4% | +375.7% | -28.5% | +47.2% | -79.6% | +32.3% | -25.7% | +1,236.9% | |
| – | -41.2% | +1,828.6% | +74.4% | -20.1% | +34.0% | -10.9% | +132.7% | -40.0% | -40.1% | +265.8% | +181.4% | +38.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -16.4% | -14.3% | +54.5% | +37.6% | +53.4% | +67.0% | +23.2% | +28.2% | +104.6% | +581.9% | +36.2% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.